Monday, October 5, 2026

AMD and Xanadu Integrate Classical Computing with Quantum Software PennyLane

AMD's high-performance computing hardware now accelerates Xanadu's PennyLane quantum software platform, demonstrating practical hybrid quantum-classical integration. The collaboration expands computational possibilities for researchers investigating quantum computing applications using AMD's existing infrastructure.

LM Salvado

March 14, 2026

AMD and Xanadu Integrate Classical Computing with Quantum Software PennyLane
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

AMD's high-performance compute technology now boosts PennyLane, Xanadu's quantum computing software platform, marking a practical integration between classical and quantum computing systems.

"Seeing AMD high-performance compute boost the performance of PennyLane is a clear proof point of how quantum and classical technologies can effectively work together," said Madhu Rangarajan from AMD's compute division.

The integration allows researchers to run hybrid quantum-classical algorithms using AMD's existing hardware infrastructure. PennyLane serves as a software layer that bridges quantum processors with classical computing resources, enabling developers to build applications that leverage both computing paradigms.

Rangarajan emphasized the collaboration "expands the boundaries of what is possible for users investigating hybrid quantum/classical computing using AMD compute today." The work addresses a key technical challenge: quantum computers require classical systems for control, error correction, and preprocessing of computational tasks.

The partnership targets enterprise and research users who need quantum simulation capabilities without dedicated quantum hardware. AMD's compute platforms can now accelerate quantum algorithm development and testing through PennyLane's framework.

This integration follows broader industry movement toward hybrid computing architectures. Classical high-performance computing remains essential for quantum applications, handling tasks like optimization problems, machine learning preprocessing, and result validation that complement quantum processors' specialized capabilities.

The collaboration positions AMD's hardware as infrastructure for quantum software development, potentially expanding the market for classical compute in quantum research facilities and enterprise AI labs exploring quantum-enhanced algorithms.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· March 10, 2026
    Xanadu and AMD Accelerate Quantum Computing for Aerospace and Engineering
  2. [2]News articleYahoo Finance· March 9, 2026
    Tech stocks today: Anthropic sues Defense Department over ban, OpenAI's robotics leader resigns
  3. [3]News articleYahoo Finance· March 6, 2026
    The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com